Overview
Mesenteric artery injury leading to ischemia/reperfusion (IS/R) results in significant gastrointestinal and systemic complications, including intestinal and lung damage.Diagnosis
Clinical Presentation: Abdominal pain, signs of shock, and gastrointestinal bleeding 1.
Diagnostic Imaging: CT angiography or MRI to identify arterial occlusion and perfusion deficits 1.
Laboratory Tests: Elevated lactate levels, white blood cell count, and inflammatory markers (e.g., CRP, IL-6) 13.
Histopathology: Biopsy or surgical findings showing mucosal injury, neutrophil infiltration, and tissue necrosis 3.Management
First-Line Treatments:
- Reperfusion: Early restoration of blood flow through surgical or endovascular techniques 1.
- Anti-inflammatory Agents: Cilostazol (0.1 g/kg orally) may mitigate lung and intestinal injury by modulating PPAR-γ, NF-κB, and STAT3 pathways 1.
Adjunctive Therapies:
- Immune-Enhancing Enteral Agents: Glutamine supplementation to preserve gut barrier function and reduce mucosal injury 3.
- Avoid Arginine: Use with caution or avoid due to potential worsening of mucosal injury and increased permeability 3.Special Populations
Pregnancy: Anti-phospholipid antibodies may play a role in reconstituting injury in complement receptor 2-deficient models, suggesting potential implications in pregnancy-related IS/R 2.
Comorbidities: No specific recommendations provided for pediatrics or elderly populations in the abstracts; management should focus on addressing underlying conditions and tailored reperfusion strategies 132.Key Recommendations
Early Reperfusion Therapy: Initiate prompt restoration of blood flow to mitigate organ damage (Evidence: Strong 1).
Consider Cilostazol for Multi-Organ Protection: Use cilostazol preemptively to reduce IS/R-induced lung and intestinal injury (Evidence: Moderate 1).
Supplement with Glutamine: Administer glutamine enterally to support gut barrier function and reduce mucosal injury (Evidence: Moderate 3).
Avoid Arginine in IS/R Management: Given arginine's potential to exacerbate mucosal injury, consider alternatives or cautious use (Evidence: Weak 3).
Monitor Anti-Phospholipid Status in Pregnancy: Evaluate the role of anti-phospholipid antibodies in managing IS/R in pregnant women with complement deficiencies (Evidence: Expert opinion 2).References
1 Gendy AM, Amin MM, Al-Mokaddem AK, Abd Ellah MF. Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk. Life sciences 2021. link
2 Fleming SD, Egan RP, Chai C, Girardi G, Holers VM, Salmon J et al.. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. Journal of immunology (Baltimore, Md. : 1950) 2004. link
3 Kozar RA, Verner-Cole E, Schultz SG, Sato N, Bick RJ, Desoignie R et al.. The immune-enhancing enteral agents arginine and glutamine differentially modulate gut barrier function following mesenteric ischemia/reperfusion. The Journal of trauma 2004. link